Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMSFree Report) by 9.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,147,927 shares of the company’s stock after purchasing an additional 193,507 shares during the period. Dimensional Fund Advisors LP owned 1.01% of Hims & Hers Health worth $19,117,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after buying an additional 1,561 shares during the last quarter. Pathstone Family Office LLC increased its stake in Hims & Hers Health by 2.8% during the third quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock worth $414,000 after acquiring an additional 1,824 shares during the last quarter. Baldwin Brothers LLC MA raised its position in Hims & Hers Health by 17.0% in the fourth quarter. Baldwin Brothers LLC MA now owns 22,128 shares of the company’s stock valued at $197,000 after purchasing an additional 3,215 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after purchasing an additional 3,429 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in shares of Hims & Hers Health by 9.6% during the 3rd quarter. Arizona State Retirement System now owns 40,050 shares of the company’s stock worth $252,000 after purchasing an additional 3,520 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total value of $2,827,653.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 63,621 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $15.17, for a total value of $965,130.57. Following the completion of the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at $2,341,413.65. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 712,224 shares of company stock valued at $10,965,174. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Trading Up 1.7 %

Shares of HIMS opened at $20.83 on Wednesday. The firm has a market capitalization of $4.47 billion, a price-to-earnings ratio of -2,083.00 and a beta of 1.08. The firm’s fifty day simple moving average is $14.63 and its 200-day simple moving average is $11.78. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $21.44.

Hims & Hers Health (NYSE:HIMSGet Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. Hims & Hers Health’s quarterly revenue was up 45.8% on a year-over-year basis. During the same period last year, the firm earned ($0.05) earnings per share. On average, analysts predict that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on HIMS shares. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Leerink Partnrs reissued a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. SVB Leerink initiated coverage on Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 price target for the company. Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. Finally, Truist Financial raised their target price on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a report on Tuesday, February 27th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.14.

View Our Latest Research Report on HIMS

Hims & Hers Health Profile

(Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

See Also

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.